Document is current

Article History

Received: 5 April 2024

Accepted: 6 May 2024

First Online: 14 May 2024

Declarations

:

: EARLI was approved by the University of California, San Francisco Institutional Review Board (IRB) and VALID by the Vanderbilt IRB.

: Consent was obtained from patients or their surrogates when possible, as previously described.

: BE received Grants for the present work from la Société de Réanimation de la langue Française, la Fondation Monohan, L’institut Servier and L’Association Limousine d’Aide aux Insuffisants Respiratoires. VEK declares a grant from the National Heart Lung and Blood Institute to his institution for the present manuscript; grants from the American Thoracic Society and Parker B. Francis Fellowship outside the present work; being part of DSMB of MODE Trial. CSC declares a grant from NIH to her institution for the present manuscript; grants from Roche Genentech, Quantum Leap Healthcare Collaborative and NIH outside the present work; consulting fees from Vasomune, Gen1e Life Science, NGM Bio, Cellenkos, Calcimedica, Arrowhead; being a co-recipient of a patent; being a council member of the International Sepsis Forum. CMH declares a grant from NIH for the present manuscript; support from DOD, NIH-NIAID and FDA to her institution outside the present work; consulting fees from Spring Discovery; being a DSMB member for regARDS Trial. KD declares being part of the University of Vermont DSBB. KDL declares grants from NIH and Quantum Leap Healthecare collaborative; consulting fees from AM Pharma, Biomerieux, Seastar Biomedical, UpToDate, Baxter; Honoraria and support from the American Society of Nephrology; and being part of advisory Boards for BOA Medical and Novartis; being an Associate Journal Editor for the American Thoracic Society. LBW declares a grant from NIH for the present manuscript; research contracts with Department of Defense, Genentech, Boehringer Ingelheim and CSL Behring; consulting fees from Arrowhead, Akebia, Santhera, Global Blood Therapeutics and Boehringer Ingelheim; being part of DSMB for CHILL Trial and SIGNET Trial; stock in Virtuoso Surgical. MAM declares grants paid to his institution outside the present work from NHLBI, NIAID, Department of Defense, Calif Institute if Regeneration, Roche Genentec and Quantum Health; consulting fees from Citius Pharmaceuticals, Gen1LifeScience, Gilead Pharmaceuticals, Novartis, Johnson and Johnson and Pilant Therapeutics. PS declares a Grant from NIGMS/NIH for the present manuscript and consulting fees from AstraZeneca and Prenosis Inc. AG, AZ, LN, NW, KNK, ES and AW declare no conflict of interests.